Trials / Not Yet Recruiting
Not Yet RecruitingNCT06702605
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
A Phase II Clinical Study of XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Evopoint Biosciences Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R/R PTCL. The study plans to enroll approximately 50 subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XNW5004 tablets | XNW5004 will be administered orally as tablets. |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2024-11-25
- Last updated
- 2024-11-25
Source: ClinicalTrials.gov record NCT06702605. Inclusion in this directory is not an endorsement.